Added Benefits of Lachrymal Substitute Gel During the Night in Patients With Moderate to Severe Dry Eye Syndrome
Overview
Dry eye syndrome is a highly prevalent ocular disease with an increasing incidence in the elderly population. Topically administered lubricants are the basis for treatment of this disease. Relief of symptoms in patients with moderate to severe dry eye disease is usually reached by the use of artificial tears during the day. Nighttime relief is often achieved by substances known to be more adhesive to the ocular surface, such as gels.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Primary Purpose: Basic Science
- Masking: Single (Investigator)
- Study Primary Completion Date: May 2016
Interventions
- Device: Thealoz Duo Gel and Thealoz Duo eye drops
- Thealoz Duo gel at night (1 drop before going to bed) + Thealoz Duo eye drops during the day (4 to 6 drops per day)
- Device: Thealoz Duo eye drops
- Thealoz Duo eye drops during the day (4 to 6 drops per day)
Arms, Groups and Cohorts
- Experimental: Patients with dry eye syndrome 1
- 20 patients with dry eye syndrome, they will receive intervention 1 for one week and then cross over to intervention 2
- Experimental: Patients with dry eye syndrome 2
- 20 patients with dry eye syndrome, they will receive intervention 2 for one week and then cross over to intervention 1
Clinical Trial Outcome Measures
Primary Measures
- Patient satisfaction when awakening (VAS)
- Time Frame: 4 weeks
Secondary Measures
- Quality of life
- Time Frame: 4 weeks
- Number of drops of Thealoz Duo instilled during the day (patient diary)
- Time Frame: 4 weeks
- Tear break up time
- Time Frame: 4 weeks
- Conjunctival and corneal staining
- Time Frame: 4 weeks
- Schirmer 1 Test
- Time Frame: 4 weeks
- OSDI questionnaire
- Time Frame: 4 weeks
- Ocular Surface Disease Index Questionnaire
Participating in This Clinical Trial
Inclusion Criteria
1. Men and women aged over 18 years 2. Signed and dated written informed consent. 3. History of dry eye syndrome for at least 3 months 4. Tear Break Up Time (BUT) ≤ 10 seconds or Schirmer I test ≤ 5 mm and ≥ 2mm 5. OSDI ≥ 22 6. Normal ophthalmic findings except dry eye syndrome 7. No administration of topical lubricants 24 hours before the screening examination Exclusion Criteria:
1. Presence of an ocular pathology judged by the investigator as incompatible with the study. 2. Any other clinical relevant ocular abnormality except DES. 3. History of allergy, known hypersensitivity to one of the components: the administered medical device product, fluorescein or lissamine green 4. History of known clinically relevant allergy 5. Medical or surgical history judged by the investigator to be incompatible with the study participation (hepatic or renal insufficiency; all chronic severe organic disease: metabolic, endocrine, neoplastic, hematological disease; severe psychiatric illness, etc.). 6. History of a recent acute illness with a recovery period within the 2 weeks before the inclusion visit (Day 0). 7. Pregnancy, lactation. 8. Pre-menopausal woman who is not using a reliable birth control method (oral contraceptives or coil) or is not surgically sterilized. 9. Participation in any high-speed or water-sports during the study without ocular protection (goggles or glasses). 10. Subject unable to understand the study instructions or unlikely to comply with the study schedule and treatment. 11. Participation in another clinical study in the 4 weeks before the start of the present study or at the same time as the present study.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Medical University of Vienna
- Provider of Information About this Clinical Study
- Principal Investigator: Gerhard Garhofer, Assoc. Prof. PD Dr. – Medical University of Vienna
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.